Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

about

Efficacy of oral tolvaptan versus 3% hypertonic saline for correction of hyponatraemia in post-operative patients.

P2860

Q47134591-95D80879-1F45-4DA2-ADF0-AAC28C3CA77E

P2860

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

Item

http://www.wikidata.org/entity/Q39446196

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

@en

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.

@nl

type

Item

label

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

@en

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.

@nl

prefLabel

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

@en

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure.

@nl

P1476

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

@en

P2093

Abigail M Chauvin

http://www.w3.org/2001/XMLSchema#string

Anshika Khare

http://www.w3.org/2001/XMLSchema#string

Poornima Vinod

http://www.w3.org/2001/XMLSchema#string

Rupesh Raina

http://www.w3.org/2001/XMLSchema#string

Vinod Krishnappa

http://www.w3.org/2001/XMLSchema#string

P2860

Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH

Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

Vasopressin receptor antagonists

Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Hyponatremia treatment guidelines 2007: expert panel recommendations.

Non-peptide arginine-vasopressin antagonists: the vaptans.

P304

87-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14740/CR553W

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28725324

http://www.w3.org/2001/XMLSchema#string

P921

AVP

heart failure

P932

5505291

http://www.w3.org/2001/XMLSchema#string

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

about

P2860

P2860

Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932